MSN Labs launches generic tablet Palborest for breast cancer treatment
The tablet, Palborest, comes in a patient-compliant pack of three strips of seven tablets each to meet the recommended three-weeks…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
breast cancer treatment
EU approves AstraZeneca’s Lynparza for patients with germline BRCA-mutated HER2-negative…
It is the first and only approved medicine targetting BRCA mutations in early breast cancer
New Novartis data show Piqray effectiveness across key biomarkers in patients with HR+/HER2-…
Biomarker analysis from phase-III Solar-1 study shows Piqray plus fulvestrant had clinical benefit regardless of presence of ESR1…
Punjab government, Roche Pharma and Niramai Health Analytix launch ‘Pink Project’…
Programme to screen 15,000 suspected females within one year and help establish a referral pathway for follow-ups for diagnosis…
US FDA approves AstraZeneca-Merck’s Lynparza to treat early-stage breast cancer
The approval was based on results from a late-stage study in which the drug showed statistically significant and clinically…
Enhertu improves both progression-free and overall survival in Destiny-Breast04 trial in patients…
First HER2-low metastatic breast cancer phase-III results for AstraZeneca and Daiichi Sankyo’s Enhertu offer potential to redefine…
Cadila Pharmaceuticals expands oncology portfolio, launches Tarzed
Tarzed is available as 440 mg injection
Existing cancer drugs to be trialled as new treatment for breast cancer
Two drugs that are already being used separately in the treatment of some prostate, renal and skin cancers, will now be tested in…
Zydus launches Ujvira (trastuzumab emtansine) for breast cancer treatment
The drug is being offered at Rs 32495 for a 100 mg vial
Dr Reddy’s Laboratories launches Fulvestrant Injection in US
Fulvestrant is an estrogen receptor antagonist indicated for the treatment of HR-positive advanced breast cancer